About Remus Pharma
Remus Pharma is a company based in Austin (United States) founded in 2015. It operates as a Reseller / Distribution and Direct-to-Consumer (D2C). The company has 34 employees as of April 07, 2024. Remus Pharma offers products and services including Critical Care Products, Neurology Products, Cardiology Products, Diabetic Products, and Generics. Remus Pharma operates in a competitive market with competitors including Pharmaron, Pfizer, Boehringer Ingelheim, Lonza and Dotmatics, among others.
- Headquarter Austin, United States
- Employees 34 as on 07 Apr, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Remus Pharmaceuticals Ltd.
-
Annual Revenue
$72.57 M (USD)191.93as on Mar 31, 2025
-
Net Profit
$3.4 M (USD)34.98as on Mar 31, 2025
-
EBITDA
$5.35 M (USD)60.71as on Mar 31, 2025
-
Latest Funding Round
-
Investors
-
Employee Count
34
as on Apr 07, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Remus Pharma
Remus Pharma is a publicly listed company on the NSE with ticker symbol REMUS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Remus Pharma
Remus Pharma offers a comprehensive portfolio of products and services, including Critical Care Products, Neurology Products, Cardiology Products, Diabetic Products, and Generics.
Critical care products are developed for urgent medical needs.
Neurology products are offered for brain-related health issues.
Cardiology products are provided for heart health management solutions.
Diabetic products are designed for managing blood sugar levels.
Affordable generics are produced for accessible healthcare solutions.
Funding Insights of Remus Pharma
Investments & Acquisitions by Remus Pharma
Financial Statements - Remus Pharma
Remus Pharma Comparisons
Competitors of Remus Pharma
Remus Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pharmaron, Pfizer, Boehringer Ingelheim, Lonza and Dotmatics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug discovery and development services for small molecules are provided.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products for treating multiple diseases are provided.
|
|
| domain | founded_year | HQ Location |
Generic drugs and clinical research services are provided globally.
|
|
| domain | founded_year | HQ Location |
CDMO services for pharma, biotech, and specialty ingredients are provided.
|
|
| domain | founded_year | HQ Location |
AI powered scientific data management and workflow automation solutions
|
|
| domain | founded_year | HQ Location |
Laboratory testing, clinical trial research, and biopharma services are provided.
|
Latest news on Remus Pharma
Frequently Asked Questions about Remus Pharma
Remus Pharma was founded in 2015.
Remus Pharma is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
As of Apr 07, 2024, the latest employee count at Remus Pharma is 34.
Annual revenue of Remus Pharma is $72.57M as on Mar 31, 2025.
Remus Pharma, along with its group of companies, is focused on marketing pharmaceutical products with specialization in Critical Care, Neurology, Cardiology, and Diabetic categories. Products are distributed through a diverse global channel to ensure accessibility. Emphasis is placed on quality standards, regulatory compliance, and clinical trials for safety. Affordable generics and niche demand-specific products are developed, alongside efforts to secure off-patent molecules for market advantage. Operations span across multiple countries with a commitment to evolving the healthcare landscape.
Remus Pharma offers Critical Care Products, Neurology Products, Cardiology Products, Diabetic Products, and Generics.
Yes, Remus Pharma is publicly traded on NSE under the ticker symbol REMUS.
The ticker symbol of Remus Pharma is REMUS on NSE.